Triple Therapy for Hypertension: Guideline Consensus

Recommended Triple‑Drug Regimen

International hypertension societies (e.g., JNC 8, ASH/ISH, NICE, Taiwan, French, ESC, ISH) uniformly recommend a three‑drug regimen consisting of a renin‑angiotensin system (RAS) blocker (ACE inhibitor or ARB) + a long‑acting dihydropyridine calcium‑channel blocker + a thiazide or thiazide‑like diuretic as the preferred third‑line strategy when two‑drug therapy fails to achieve target blood pressure [1][2][3][4][5][6]7.
The 2020 International Society of Hypertension (ISH) guideline specifies a stepwise approach: start with an ACE / ARB, add a dihydropyridine CCB, then introduce a thiazide (or thiazide‑like) diuretic as the third step [4][5]6.
The 2024 European Society of Cardiology (ESC) guideline advises escalation to the above triple combination if a two‑drug regimen does not control blood pressure, preferably using a single‑pill formulation 7.

Thiazide diuretics increase renin release, which is counter‑acted by the concurrent ACE inhibitor or ARB, producing an additive blood‑pressure‑lowering effect; this synergism is highlighted in the 2018 Circulation review 8.

Long‑acting thiazide‑like agents (chlorthalidone or indapamide) are favored over traditional thiazides because they have demonstrated greater reductions in cardiovascular events 9.
The 2018 ACC/AHA guideline explicitly recommends prioritizing thiazide‑like diuretics with proven cardiovascular benefit 8.

Fixed‑dose single‑pill combinations of the three agents are strongly endorsed to improve adherence and simplify therapy 7.
Multiple guideline bodies (including those summarized in Drugs 2014) note that single‑pill regimens reduce pill burden and enhance long‑term compliance [1][10].

If blood pressure remains uncontrolled on optimal triple therapy, add spironolactone as the preferred fourth‑line agent for resistant hypertension [9][7].
The ESC 2024 guideline also recommends considering spironolactone in this context 7.
When spironolactone is not tolerated, alternative agents (amiloride, doxazosin, eplerenone, clonidine, or beta‑blockers) may be used [4][5][6][7].

Combining two RAS blockers (e.g., ACE inhibitor + ARB or either with aliskiren) is contraindicated because it raises cardiovascular and renal risk without added benefit [10][7]8.
Co‑prescribing a thiazide diuretic with a beta‑blocker should be avoided when possible due to an increased risk of new‑onset diabetes 10.
Patients on ACE inhibitors, ARBs, or diuretics should have serum creatinine and potassium monitored at least annually 9.
Verify that the thiazide component of any triple‑pill formulation is dosed adequately, as many fixed‑dose products contain sub‑therapeutic amounts 8.

Aim to achieve target blood pressure within three months of initiating or adjusting therapy [4][5][6][7].
Re‑evaluate and modify the regimen every 2–4 weeks until the blood pressure goal is reached [1][2]10.